GP130 cytokines and bone remodelling in health and disease

被引:101
作者
Sims, Natalie A. [1 ]
Walsh, Nicole C.
机构
[1] St Vincents Inst, Fitzroy, Vic 3065, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
Arthritis; Bone remodeling; gp130; IL-6; Osteoblast; Osteoclast; Periodontal disease; LEUKEMIA INHIBITORY FACTOR; CILIARY NEUROTROPHIC FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; HUMAN ARTICULAR CHONDROCYTES; IL-6 SIGNAL TRANSDUCER; ONCOSTATIN-M; RHEUMATOID-ARTHRITIS; PARATHYROID-HORMONE; FACTOR-RECEPTOR; TNF-ALPHA;
D O I
10.5483/BMBRep.2010.43.8.513
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cytokines that bind to and signal through the gp130 co-receptor subunit include interleukin (IL)-6, IL-11, oncostatin M (OSM), leukemia inhibitory factor (LIE), cardiotrophin-1 (CT-1), and ciliary neutrophic factor (CNTF). Apart from contributing to inflammation, gp130 signalling cytokines also function in the maintenance of bone homeostasis. Expression of each of these cytokines and their ligand-specific receptors is observed in bone and joint cells, and bone-active hormones and inflammatory cytokines regulate their expression. gp130 signalling cytokines have been shown to regulate the differentiation and activity of osteoblasts, osteoclasts and chondrocytes. Furthermore, cytokine and receptor specific gene-knockout mouse models have identified distinct roles for each of these cytokines in regulating bone resorption, bone formation and bone growth. This review will discuss the current models of paracrine and endocrine actions of gp130-signalling cytokines in bone remodelling and growth, as well as their impact in pathologic bone remodelling evident in periodontal disease, rheumatoid arthritis, spondylarthropathies and osteoarthritis. [BMB reports 2010; 43(8): 513-523]
引用
收藏
页码:513 / 523
页数:11
相关论文
共 124 条
[1]  
Al-Awadhi A, 1999, J RHEUMATOL, V26, P1250
[2]   OSTEOBLASTS DISPLAY RECEPTORS FOR AND RESPONSES TO LEUKEMIA-INHIBITORY FACTOR [J].
ALLAN, EH ;
HILTON, DJ ;
BROWN, MA ;
EVELY, RS ;
YUMITA, S ;
METCALF, D ;
GOUGH, NM ;
NG, KW ;
NICOLA, NA ;
MARTIN, TJ .
JOURNAL OF CELLULAR PHYSIOLOGY, 1990, 145 (01) :110-119
[3]   Altered Skeletal Expression of Sclerostin and Its Link to Radiographic Progression in Ankylosing Spondylitis [J].
Appel, Heiner ;
Ruiz-Heiland, Gisela ;
Listing, Joachim ;
Zwerina, Jochen ;
Herrmann, Martin ;
Mueller, Ruediger ;
Haibel, Hildrun ;
Baraliakos, Xenofon ;
Hempfing, Axel ;
Rudwaleit, Martin ;
Sieper, Joachim ;
Schett, Georg .
ARTHRITIS AND RHEUMATISM, 2009, 60 (11) :3257-3262
[4]   Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation [J].
Atkins, GJ ;
Haynes, DR ;
Geary, SM ;
Loric, M ;
Crotti, TN ;
Findlay, DM .
BONE, 2000, 26 (06) :653-661
[5]  
Barkhordar RA, 1999, ENDOD DENT TRAUMATOL, V15, P26
[6]   Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal osteoblastic cells [J].
Bellido, T ;
Stahl, N ;
Farruggella, TJ ;
Borba, V ;
Yancopoulos, GD ;
Manolagas, SC .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (02) :431-437
[7]   Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation [J].
Bellido, T ;
Borba, VZC ;
Roberson, P ;
Manolagas, SC .
ENDOCRINOLOGY, 1997, 138 (09) :3666-3676
[8]   The "enthesis organ" concept - Why enthesopathies may not present as focal insertional disorders [J].
Benjamin, M ;
Moriggl, B ;
Brenner, E ;
Emery, P ;
McGonagle, D ;
Redman, S .
ARTHRITIS AND RHEUMATISM, 2004, 50 (10) :3306-3313
[9]   Histopathologic changes at "synovio-entheseal complexes" suggesting a novel mechanism for synovitis in osteoarthritis and spondylarthritis [J].
Benjamin, Michael ;
McGonagle, Dennis .
ARTHRITIS AND RHEUMATISM, 2007, 56 (11) :3601-3609
[10]   SOST/sclerostin, an osteocyte-derived negative regulator of bone formation [J].
Bezooijen, RL ;
ten Dijke, P ;
Papapoulos, SE ;
Löwik, CWGM .
CYTOKINE & GROWTH FACTOR REVIEWS, 2005, 16 (03) :319-327